每经AI快讯，赛诺医疗（SH 688108，收盘价：33.38元）8月25日晚间发布公告称，近日，赛诺医疗科 学技术股份有限公司控股子公司赛诺神畅医疗科技有限公司收到国家药品监督管理局颁发的《中华人民 共和国医疗器械注册证》。产品名称为"一次性使用微导管"。 每经头条（nbdtoutiao）——A股成交连续8天破2万亿元，券商招聘也来了！行业巨头秋招"求才"，25个 岗位都有什么特点？ （记者 胡玲） 2024年1至12月份，赛诺医疗的营业收入构成为：医疗器械行业占比99.83%，其他业务占比0.17%。 截至发稿，赛诺医疗市值为139亿元。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...

New Stock Issuance - New stock issuance for Huaxin Jingke at a price of 18.60 on August 25, 2025[1] - Shenkou Co. (stock code: 002633) has a tender offer period from July 29 to August 27, 2025[1] - Fushun Special Steel (stock code: 600399) has a tender offer period from August 12 to September 10, 2025[1] Market Alerts - Dongxin Co. (stock code: 688110) reported severe abnormal fluctuations on August 16, 2025[1] - ST Suwu (stock code: 600200) and ST Zhongdi (stock code: 000609) both have announcements dated August 25, 2025[1] - Multiple companies including Zhehai Deman (stock code: 688577) and Huaguang Huaneng (stock code: 600475) have announcements related to abnormal fluctuations on August 23, 2025[1] Additional Information - The report includes links to detailed announcements for various companies, providing transparency and access to further information[1] - The document highlights the importance of monitoring stock performance and market trends for informed investment decisions[1]

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-040 赛诺医疗科学技术股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、说明会类型 赛诺医疗科学技术股份股份有限公司（以下简称"赛诺医疗"或"公司"） 于 2025 年 08 月 22 日在上海证券交易所网站（http://www.sse.com.cn）上披露 了《赛诺医疗科学技术股份有限公司 2025 年半年度报告》及其摘要。 为加强与投资者的深入交流，便于广大投资者更全面深入地了解公司，在上 海证券交易所的支持下，公司计划于 2025 年 09 月 03 日 16:00-17:00 在上证路 演中心（网址：https://roadshow.sseinfo.com/）以网络文字互动问答的方式 举行赛诺医疗 2025 年半年度业绩说明会，与广大投资者进行充分交流，解答投 资者普遍关注的问题。 二、说明会召开的时间、地点 1、会议召开时间：2025 年 09 月 03 日 16:0 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-039 赛诺医疗科学技术股份有限公司关于 子公司产品获得国内医疗器械注册证的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）控股子公 司赛诺神畅医疗科技有限公司（以下简称"赛诺神畅"）收到国家药品监督管理局（以下 简称"国家药监局"）颁发的《中华人民共和国医疗器械注册证》，现将相关情况公告如 下： 适用范围：该产品用于一般性血管内操作，包括在神经血管内输注诊断性制剂(造 影剂)和适当的器械(弹簧圈、支架)。 有效期至：2030 年 8 月 21 日 二、医疗器械基本情况 本次获得《医疗器械注册证》的一次性使用微导管，是由公司控股子公司赛诺神畅 自主研发并进行生产的一款导管产品。该产品为单腔器械，有半刚性的近端部分和柔韧 的远端部分。微导管手柄上有鲁尔接头可以用来连接附件。微导管远端有不透射线标记， 可以在 X 射线下清晰可辨。微导管外表面涂有亲水涂层，能减少血管 ...

投资要点 事件：公司近期发布2025 年中报。2025 年上半年，公司实现收入2.40亿元（+12.53%，同比，下同）， 实现归母净利润0.14 亿元（+296.54%），实现扣非归母净利润0.08 亿元（+163.35%）。2025 单Q2 季 度，公司实现收入1.40 亿元（+13.86%），实现归母净利润0.11 亿元（+110.56%），实现扣非归母净利 润0.07 亿元（+42.83%），业绩符合我们预期。 公司冠脉介入耗材国内外推进顺利。冠脉介入方面，2025 年上半年，公司冠脉支架及球囊产品持续参 与国家冠脉支架及各省市球囊产品集采，产品销量稳步上升。截至2025 年8 月22 日，全国大部分省市 冠脉支架带量集采第二轮第三周期已完成落地执行。除部分省市外，公司冠脉球囊产品已完成全国大部 分省市的续采工作。此外，公司在河北2023 年底组织的京津冀"3+N"联盟28 种医用耗材集中带量采购 项目中中选的棘突球囊也在除西藏外的其他联盟省份完成落地。公司冠脉药物洗脱支架系统先后在阿根 廷，厄瓜多尔、越南等国家和地区获得海外注册证；公司冠脉球囊扩张导管（SC HONKYTONKTM） 和（NC RO ...

| 股票名称 | 监控开始日期 监控结束日期 异动开始日期 | | --- | --- | | 思泉新材 | 2025-08-22 2025-09-04 未披露 | | 301489 | | | *ST苏吴 | 2025-08-21 2025-09-03 未披露 | | 600200 | | | 赛诺医疗 | 2025-08-19 2025-09-01 2025-08-07 | | 688108 | | | 东芯股份 | 2025-08-18 2025-08-29 2025-07-07 | | 688110 | | | 赛诺医疗 | 2025-08-18 2025-08-29 2025-08-07 | | 688108 | | | 淳中科技 | 2025-08-15 2025-08-28 未披露 | | 603516 | | | 长城军工 | 2025-08-14 2025-08-27 2025-07-31 | | 601606 | | 根据交易所规则,股票交易出现严重异常波动情形后10个交易 日内,连续竞价阶段1分钟内单向申报买入(卖出)单只严重异常 波动股票金额巨大的,交易所对有关交易行为予以重点监控。 ...

Core Viewpoint - Sino Medical reported a significant increase in net profit and revenue for the first half of 2025, despite recent stock price volatility and a notable drop in share price over three consecutive trading days [4][6]. Trading Information Summary - On August 22, 2025, Sino Medical's stock closed at 32.7 yuan, down 4.44%, with a turnover rate of 14.54% and a trading volume of 605,100 shares, amounting to a total transaction value of 2.01 billion yuan [1]. - The capital flow on the same day showed a net outflow of 209 million yuan from main funds, accounting for 10.4% of the total transaction value, while retail investors saw a net inflow of 7.39 million yuan, representing 3.68% of the total [2][7]. Shareholder Changes - As of June 30, 2025, the number of shareholders for Sino Medical was 11,100, an increase of 46 from March 31, 2025, reflecting a growth rate of 0.42% [3][7]. Performance Disclosure Highlights - For the first half of 2025, Sino Medical achieved a main revenue of 240 million yuan, a year-on-year increase of 12.53%, and a net profit attributable to shareholders of 13.84 million yuan, up 296.54% [4][5]. - The second quarter alone saw a main revenue of 140 million yuan, a 13.86% increase year-on-year, and a net profit of 10.87 million yuan, reflecting a 110.56% rise [4]. Company Announcements Summary - Sino Medical's total assets as of the end of the reporting period were approximately 1.31 billion yuan, a 0.70% increase from the previous year, while the net assets attributable to shareholders rose by 3.13% to approximately 894 million yuan [5]. - The company’s R&D expenditure accounted for 32.36% of its revenue, a decrease of 10.80 percentage points compared to the previous year [5].

证券研究报告·公司点评报告·医疗器械 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 343.26 | 458.74 | 573.42 | 745.45 | 969.09 | | 同比（%） | 77.99 | 33.64 | 25.00 | 30.00 | 30.00 | | 归母净利润（百万元） | (39.63) | 1.50 | 31.41 | 58.18 | 79.90 | | 同比（%） | 75.59 | 103.78 | 1,997.13 | 85.21 | 37.34 | | EPS-最新摊薄（元/股） | (0.10) | 0.00 | 0.08 | 0.14 | 0.19 | | P/E（现价&最新摊薄） | (343.29) | 9,083.21 | 433.13 | 233.86 | 170.27 | [Table_Tag] [Table_Summary] 投资要点 ◼ 颅内自膨载药支架 ...

Core Viewpoint - Sino Medical (688108) experienced significant stock price fluctuations, with a recent decline of 5.41% and a peak price of 47.0 yuan, indicating volatility in the market [1][2]. Trading Information Summary - Sino Medical's stock was listed on the "Dragon and Tiger List" twice this week due to price deviation limits being reached, marking the second and third occurrences in five trading days [2][6]. Shareholder Changes - As of June 30, 2025, the number of shareholders for Sino Medical increased to 11,100, reflecting a growth of 46 shareholders or 0.42% since March 31, 2025. The average shareholding per account rose slightly to 37,500 shares, with an average market value of 420,900 yuan [3]. Performance Disclosure Highlights - For the first half of 2025, Sino Medical reported a main revenue of 240 million yuan, a year-on-year increase of 12.53%. The net profit attributable to shareholders reached 13.84 million yuan, up 296.54%, while the non-recurring net profit was 7.98 million yuan, increasing by 163.35%. In Q2 2025, the company achieved a revenue of 140 million yuan, a 13.86% year-on-year growth, with a net profit of 10.87 million yuan, reflecting a 110.56% increase [4][6]. Company Announcement Summary - Sino Medical's subsidiary received FDA breakthrough device designation for its COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter, although this does not guarantee future approval for market entry. The company's blood flow-directed mesh stent products have been listed and won bids in several provinces, but sales and implantation forecasts remain uncertain. The projected net profits for 2023 and 2024 are -39.63 million yuan and 1.50 million yuan, respectively, with an expected net profit of 13.84 million yuan for the first half of 2025 [5][6].

证券之星消息，截至2025年8月22日收盘，赛诺医疗(688108)报收于32.7元，下跌4.44%，换手率 14.54%，成交量60.51万手，成交额20.1亿元。 8月22日的资金流向数据方面，主力资金净流出2.09亿元，占总成交额10.4%，游资资金净流入1.35亿 元，占总成交额6.72%，散户资金净流入7390.73万元，占总成交额3.68%。 | 日期 | 涨跌幅 | 融资余额(元) | 融资净买入(元) 融券余量(股) | | 融券净卖出(股) | 融资融券余额(元) | | --- | --- | --- | --- | --- | --- | --- | | 2025-08-22 | -4.44% | 265.6 | -1269.64万 | 0.0 | 0.0 | 9.39亿 | | 2025-08-21 | -8.21% | 9.51亿 | 1938.34万 | 0.0 | -200.0 | 9.51亿 | | 2025-08-20 | -7.77% | 9.32亿 | -2651.39万 | 200.0 | 0.0 | 9.32亿 | | 2025-08-19 | -2.56% | 9. ...